Dr Reddy’s Q2 Profit Falls 36%; Semaglutide Relaunch Planned for November
Dr Reddy’s Laboratories reported September-quarter profit of Rs.925 crore, down 36% year on year, and consolidated revenue of Rs.8,671 crore, down 1.5%. The company plans to relaunch semaglutide in November.
Mumbai, Oct. 23 -- Dr Reddy's Laboratories posted its results for the September quarter on Friday, with profit down 36% year-on-year to Rs.925 crore and consolidated revenue down 1.5% on-year to Rs.8,671 crore. Growth was primarily impacted by lower sales of blood cancer drug lenalidomide (Revlimid…